MBX Biosciences, Inc. Common Stock (MBX)

About MBX Biosciences, Inc. Common Stock

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 165 institutions reported holding MBX, with 55.5 million shares worth $3.1 billion in aggregate. The largest reported holder was Frazier Life Sciences Management, with 6.7 million shares worth $367.2 million. Of the 5 largest holders listed below, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions